



Immune Kidney Disease 360 (IKD 360) Northwest
CSL Collaborative Working Executive Summary

Project title	Immune Kidney Disease 360 (IKD 360) Northwest Collaborative Working Project
Project rationale	Immune Kidney Diseases (IKD) encompass a group of immune-mediated inflammatory conditions affecting the kidney, e.g. including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy, membranoproliferative glomerulonephritis (MPGN) as well as systemic immune mediated disorders such as small vessel vasculitides and systemic lupus erythematosus, transplant-related GN, and other immune-mediated glomerular disorders. Despite being rare diseases, IKDs account for 10–20% of cases in patients requiring dialysis or kidney transplantation. Care for IKD remains fragmented, with disparities in access, variability in treatment pathways, and limited integration of research findings into routine clinical practice. IKD360 seeks to address these gaps by uniting the clinical expertise, infrastructure, and shared vision of two leading regional renal centres, University Hospitals of Liverpool Group and Manchester University NHS Foundation Trust in partnership with the North-West Kidney Network to establish a unified, scalable IKD care and research platform for Northwest England. This 12-month project aims to achieve the following: • Streamline service and pathways ○ Evaluate and understand how IKD patients access care across current pathways ○ Identify delays and variation in diagnostic and treatment processes. ○ Generate evidence to inform future service improvement, pathway redesign, and development of a more efficient and equitable regional IKD model. • Support therapeutic innovation ○ Improve access to guideline based and novel therapies

	○ Strengthen innovation by enhancing participation in clinical and real-world research. • Share best practice with other centres: ○ Develop peer-to-peer education with other hospitals ○ Presentations at appropriate conference.
Project objectives	This project aims to deliver: Patients: • Improved patient experience ○ Consistent and equitable access to IKD care supported by guidelines ○ Reduced delays in diagnosis, biopsy, MDT review and treatment initiation. ○ Improved access to educational tools and resources to support self-management and engagement in care. NHS: • Improved understanding of current IKD pathways ○ Comprehensive mapping of existing pathways to identify bottlenecks, duplication, operational inefficiencies, and capacity gaps. • Evidence-driven service improvement and planning ○ Use of real-world data to inform clinical governance, undertake an options appraisal, and guide redesign of IKD services. • A unified and equitable regional IKD model ○ Development of standardised pathways, local guidelines and a secure regional data registry to ensure equitable and timely care across the Northwest. Industry: • Strengthened collaborative partnership ○ Between CSL Vifor and NHS organisations across the Northwest and nationally. • Improved understanding of real-world IKD care ○ To support appropriate, timely, and evidence-based use of therapies where clinically indicated. • Access to anonymised, aggregated service-evaluation data ○ To enhance disease understanding and inform future collaborative initiatives.
Financial arrangements	Project Support: CSL Vifor financial contribution £188,620 North West Kidney Network & host Trust sites indirect contribution £102,398

Summary of the roles and responsibilities of each party	Senior Network Manager to oversee project delivery for North West Kidney Network Head of Market Access, Value & Pricing UK and Ireland to oversee project delivery for CSL
Plans for publication	A project summary report will be published on the CSL website within 6 months of project completion
Project period	August 2026 for a 12-month duration